Belite Bio, Inc - ADR

The momentum for this stock is not very good. Belite Bio, Inc - ADR is not very popular among insiders. Tradey thinks it is not wise to invest in Belite Bio, Inc - ADR.

News

Buy Rating for Belite Bio, Inc. on Strong Global Clinical Progress and Regulatory Advantages for Tinlarebant

TipRanks Financial Blog Belite Bio, Inc. ADR (BLTE - Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Oku...\n more…

Belite Bio announces first patient dosed in Phase 2/3 DRAGON II trial

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease

Globe Newswire Phase 2/3 of the DRAGON II trial will evaluate the efficacy, safety, and tolerability of Tinlarebant in approximately 60 adolescent STGD1 subjects across the U.S., U.K., and JapanPhase 1b of DRAGON...\n more…

Belite Bio to Participate in Three Upcoming Investor Conferences

Globe Newswire SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...\n more…

Belite Bio names Hendrik P. N. Scholl as chief medical officer

Seeking Alpha - Healthcare Belite Bio names Hendrik P. N. Scholl as chief medical officer...\n more…